How Biosimilar Insulin Manufacturing Is Expanding Global Treatment Accessibility

4% share in 2025. Established pharmaceutical manufacturing facilities, healthcare distribution networks, and diabetes treatment infrastructure support regional market activity.

How Biosimilar Insulin Manufacturing Is Expanding Global Treatment Accessibility
insulin market

The global insulin market covers therapeutic insulin formulations used to regulate blood glucose levels and manage diabetes. These include human insulin, analog insulin, and rapid-acting, short-acting, intermediate-acting, and long-acting products. Insulin therapies are widely administered through hospitals, clinics, pharmacies, and home healthcare settings to maintain blood sugar control and reduce diabetes-related complications.

The global insulin market size was valued at USD 21.13 billion in 2025 and is projected to grow from USD 21.90 billion in 2026 to USD 29.13 billion by 2034, registering a CAGR of 3.63% during the forecast period 2026–2034. North America dominated the market with a 38.4% share in 2025, while Asia Pacific is projected to register the fastest regional CAGR of 6.41%.

For detailed market insights, growth forecasts, and competitive analysis, visit: https://straitsresearch.com/report/insulin-market

Insulin Market Drivers

Diabetes Prevalence and Long-Term Insulin Therapy Requirements Drive Market

Diabetes prevalence creates sustained demand for insulin therapy among individuals with type 1 diabetes and patients with type 2 diabetes who require insulin treatment. Long-term administration helps maintain blood glucose control and reduce the risk of diabetes-related complications. Continuous treatment requirements support recurring insulin purchases through healthcare facilities and pharmacies.

Early Diabetes Diagnosis and Timely Initiation of Insulin Treatment

Diabetes screening programs help healthcare providers identify elevated blood glucose levels and assess treatment requirements. Timely diagnosis enables clinicians to initiate insulin therapy when medically indicated and monitor treatment effectiveness. Early identification of patients requiring insulin supports prescription volumes across clinical care settings.

Government Diabetes Management and Insulin Procurement Programs

Government diabetes management programs support access to essential insulin therapies through public healthcare systems. Institutional procurement creates purchasing opportunities for pharmaceutical manufacturers and strengthens medicine availability across treatment facilities. Established supply arrangements help healthcare providers maintain insulin access for patients requiring continuous therapy.

Insulin Market Trends

Development of Oral Insulin Formulations Using Nanoparticle-Based Drug Delivery Systems

The insulin market analysis shows that demand for convenient diabetes treatment and reduced injection discomfort encourages research into oral insulin formulations. Polymeric nanoparticles, lipid-based carriers, and protective coatings are being investigated to protect insulin from digestive enzymes and improve gastrointestinal absorption. For instance, research involving chitosan-based insulin nanoparticles demonstrates potential for oral delivery, although these formulations remain under development.

Adoption of Biosimilar Insulin Products to Improve Treatment Affordability

Demand for affordable diabetes treatment encourages pharmaceutical manufacturers and healthcare providers to consider approved biosimilar insulin products. Advanced biomanufacturing and comparative analytical testing support the development of products that meet regulatory similarity requirements. Wider availability of biosimilar alternatives increases procurement choices, encourages price competition, and supports access to insulin therapy.

Insulin Market Segmentation

By Type

Analog insulin is expected to achieve a CAGR of 5.46% during the forecast period, supported by predictable action profiles, flexible dosing options, and effective blood glucose management. Human insulin is projected to record a CAGR of 3.64%, supported by affordability, established clinical use, and availability through public healthcare programs.

By Product

Long-acting insulin accounted for a 36.4% market share in 2025, supported by sustained blood glucose control, reduced dosing frequency, and basal insulin requirements. Fast-acting insulin is expected to achieve a CAGR of 5.72% during the forecast period, driven by demand for rapid mealtime glucose management and flexible treatment regimens.

By Applications

Type II diabetes accounted for a 55.6% market share in 2025, supported by disease prevalence and long-term insulin requirements among patients needing advanced treatment. Type I diabetes is projected to record a CAGR of 4.62% during the forecast period, supported by lifelong insulin dependence and adoption of personalized insulin delivery technologies.

By Distribution Channel

Drug stores & retail pharmacies accounted for a 46.8% market share in 2025 and are expected to achieve a CAGR of 5.03% during the forecast period. Established pharmacy networks, convenient prescription access, and recurring medicine purchases support retail distribution, while hospitals are projected to grow at a CAGR of 4.51%.

Insulin Market Regional Insights

North America Insulin Market

North America dominated the global insulin market with a 38.4% share in 2025. Established pharmaceutical manufacturing facilities, healthcare distribution networks, and diabetes treatment infrastructure support regional market activity.

U.S. Insulin Market

The U.S. maintains specialized injectable medicine manufacturing capabilities through Novo Nordisk's facilities in Clayton, North Carolina. Pharmaceutical filling and packaging operations contribute to diabetes treatment supply, while investments in automated production infrastructure support manufacturing efficiency. Advanced processing technologies help maintain reliable insulin availability across healthcare distribution channels.

Canada Insulin Market

Canada is managing changes in diabetes medicine availability following Wockhardt UK's discontinuation of animal-sourced insulin products. Health Canada's regulatory oversight and supply notifications help healthcare professionals identify alternative human insulin and insulin analogue formulations. Medical supervision supports appropriate treatment transitions for affected patients.

Asia Pacific Insulin Market

Asia Pacific is projected to register the fastest regional CAGR of 6.41% during 2026–2034. Regulatory approvals for advanced insulin formulations, biosimilar manufacturing capabilities, and diabetes treatment development support regional market growth.

Japan Insulin Market

Japan has authorized Novo Nordisk's once-weekly fixed-dose combination of insulin icodec and semaglutide for adults with type 2 diabetes requiring insulin treatment. The combination integrates basal insulin and GLP-1 receptor agonist therapy into a single prefilled injection pen. Less frequent administration offers eligible patients an additional diabetes management option.

China Insulin Market

China has approved Novo Nordisk's Awiqli insulin icodec injection, introducing an additional long-acting diabetes treatment option. Weekly administration provides an alternative to daily basal insulin regimens for eligible adults with type 2 diabetes. Extended-duration formulations create opportunities for pharmaceutical manufacturers to address treatment convenience.

India Insulin Market

India contributes to international biosimilar insulin production through Bengaluru-based Biocon Biologics, which developed Semglee insulin glargine and Kirsty insulin aspart. Regulatory acceptance in overseas markets demonstrates domestic capabilities in complex biologics development. Export opportunities support manufacturers supplying alternative insulin formulations to international healthcare systems.

Europe Insulin Market

Europe is projected to register a CAGR of 4.18% during 2026–2034. Pharmaceutical manufacturing investments, regulatory approvals, and advanced production technologies support regional insulin supply and market development.

U.K. Insulin Market

The U.K. Medicines and Healthcare products Regulatory Agency has granted regulatory clearance for Biocon Biologics' additional insulin fill-finish manufacturing unit in Malaysia. Approval broadens authorized production arrangements for Semglee insulin glargine. Additional manufacturing capacity offers greater flexibility in pharmaceutical supply planning for the British market.

Germany Insulin Market

Germany is developing an automated insulin manufacturing facility at Sanofi's BioCampus in Frankfurt. Digital production systems and artificial intelligence are being incorporated into pharmaceutical operations. Integration of active pharmaceutical ingredient manufacturing with filling, device assembly, and packaging activities supports production coordination and international insulin supply chains.

Insulin Market Competitive Landscape

The insulin market is highly consolidated, with competition among multinational pharmaceutical manufacturers, biotechnology companies, biosimilar producers, and diabetes treatment specialists. Novo Nordisk, Eli Lilly, Sanofi, Biocon, and Boehringer Ingelheim are estimated to account for a cumulative insulin market share of 40–45%. Competition focuses on formulation innovation, manufacturing capacity, treatment effectiveness, affordability, regulatory approvals, and supply reliability.

Conclusion

The insulin market outlook reflects sustained demand for diabetes management, long-term therapy, and accessible insulin formulations. Long-acting insulin, type II diabetes treatment, and retail pharmacy distribution represent major market segments, while analog and fast-acting insulin products offer growth opportunities. North America maintains the largest regional share, whereas Asia Pacific is projected to grow fastest. Biosimilar insulin development, advanced manufacturing technologies, and research into alternative delivery systems continue to influence market development.

About Us

Straits Research provides market intelligence, industry analysis, market forecasts, and competitive assessments across global industries. Its research helps organizations understand market dynamics, identify opportunities, and make informed strategic decisions.

Contact Us

Website: https://straitsresearch.com

Email: [email protected]

U.S.: +1 646 905 0080

India: +91 8087085354

U.K.: +44 203 695 0070